Huaxia Eye Hospital Group Co., Ltd.

Huaxia Eye Hospital Group Co., Ltd.

SSZSE:301267
14.72
CNY
-0.01
(-0.07%)
0.56EPS
26.88P/E
12.73BMarket Cap
May 04Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.06
2.87
3.31
3.36
4.09
4.22
4.76
4.79
4.98
5.02
Basic EPS, GAAP
0.1
0.22
0.29
0.45
0.61
0.67
0.79
0.51
0.53
0.56
Free Cash Flow per Basic Share
-0.08
-0.06
0.25
0.57
0.83
0.7
0.61
0.64
0.76
- -
Dividend per Share
- -
- -
0.02
0.01
- -
- -
0.19
0.11
0.31
0.27
Book Value per Share
1.29
1.49
1.45
1.89
2.44
6.09
6.73
6.9
6.27
6.66
Tangible Book Value per Share
1.15
1.33
1.29
1.73
2.29
5.89
6.4
6.12
5.44
5.82
Basic Weighted Avg Shares
774
746
742
749
750
767
843
840
831
839
Sales/Revenue/Turnover
1,597
2,146
2,456
2,515
3,064
3,233
4,013
4,027
4,139
4,209
Operating Margin (%)
10.97
13.14
12.52
19.7
22.51
23.11
22.73
15.79
15.41
15.75
Depreciation Expense
95
122
150
154
266
274
274
309
333
- -
Net Income, GAAP
77
164
218
334
455
514
666
429
441
473
Effective Tax Rate (%)
58.69
40.16
35.63
30.08
22.1
22.09
20.71
23.96
24.53
25.24
Profit Margin (%)
4.85
7.65
8.87
13.3
14.85
15.89
16.59
10.64
10.65
11.24
Working Capital
-146
-21
-63
189
553
3,827
3,888
3,759
3,234
3,480
LT Debt
67
228
207
642
545
623
619
833
929
743
Total Equity
1,005
1,148
1,122
1,452
1,849
5,130
5,718
6,023
5,453
5,778
Return on Invested Capital (%)
- -
13.05
14.54
19.34
21.8
13.39
12.41
7.22
6.79
- -
Return on Capital (%)
- -
16.45
22.8
21.21
22.38
13.12
11.13
6.89
7.12
- -
Return on Common Equity (%)
- -
15.76
19.76
26.72
27.98
14.79
12.36
7.49
7.96
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
233
234
335
LT Borrowings
111
111
33
LT Finance Leases
738
720
710
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
840
840
840
Market Capitalization
14,162
12,256
12,734

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,586
4,684
4,775
Cash, Cash Equivalents & STI
3,894
3,980
4,037
Accounts Receivable, Net
341
317
332
Inventories
176
197
192
Total Current Liabilities
1,200
1,323
1,295
Payables & Accruals
- -
- -
- -
ST Debt
233
234
335
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
42.44%
-9.47%
Free Cash Flow
- -
10.13%
17.55%
Net Income, GAAP
- -
9.15%
2.8%
Sales/Revenue/Turnover
- -
10.92%
2.78%
Total Cash Common Dividend
- -
6,286.44%
183.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
978
1,072
1,131
845
4,027
2025
1,093
1,046
- -
867
4,139
2026
1,150
1,035
1,156
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.13
0.19
0.01
0.51
2025
0.18
0.16
- -
0.01
0.53
2026
0.2
0.14
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
0.09
0.31
2026
- -
- -
0.17
- -
- -

Company Description

CEO
Qing Can Su
Full Time Employees
8,200
Sector
Health services
Industry
Hospital/Nursing management
Address
Xiamen China
IPO Date
Nov 7, 2022
Business
Huaxia Eye Hospital Group Co., Ltd. is a China-based healthcare services provider specializing in comprehensive ophthalmic medical and optical care. Founded in 2004 and headquartered in Xiamen, Fujian Province, the company operates an extensive nationwide network of specialized eye hospitals and optometry centers across mainland China. Huaxia Eye Hospital Group delivers a full spectrum of clinical ophthalmology and vision health services, organized into core specialty segments including: refractive surgery, offering small incision lenticule extraction (SMILE), femtosecond-assisted laser in situ keratomileusis (FS-LASIK), and implantable collamer lens (ICL/TICL) surgeries for myopia, hyperopia, and astigmatism; cataract and presbyopia treatment, providing femtosecond laser-assisted cataract surgery, micro-incision phacoemulsification, and premium multifocal, trifocal, and extended depth of focus (EDOF) intraocular lens implantations; ocular fundus and vitreoretinal care, encompassing vitrectomy, laser photocoagulation, and anti-vascular endothelial growth factor (anti-VEGF) therapies for macular degeneration, diabetic retinopathy, and retinal detachment; optometry and pediatric ophthalmology, comprising medical refraction, vision training, strabismus and amblyopia correction, and the prescription and dispensing of orthokeratology (Ortho-K) lenses, defocus lenses, spectacles, and contact lenses; ocular surface and corneal disease management, covering corneal transplantation, keratoconus cross-linking, and intense pulsed light (IPL) therapies for dry eye syndrome; and glaucoma, oculoplastic, and orbital disease interventions, including minimally invasive glaucoma surgery (MIGS), trabeculectomy, and reconstructive ocular procedures. In addition to clinical procedures, the company sells ophthalmic pharmaceuticals, surgical consumables, and customized optical products. In recent strategic developments, Huaxia Eye Hospital Group has accelerated its nationwide footprint expansion through targeted equity acquisitions and consolidations of regional ophthalmic hospitals across multiple Chinese provinces. The company has also expanded its digital healthcare capabilities by implementing artificial intelligence-driven diagnostic imaging systems for rapid ocular disease screening, deployed next-generation femtosecond laser and premium lens technologies across its hospital network, and strengthened clinical research and residency partnerships with leading academic medical institutions.